Researchers from Jouf University and affiliated organizations have reported the discovery of novel cyclooxygenase-2 (COX-2) inhibitors as potential nonacidic anti-inflammatory agents.
Inmagene Biopharmaceuticals Co. Ltd. has obtained IND approval from the FDA for IMG-008, the company's novel long-acting antagonistic humanized monoclonal antibody that specifically targets human IL-36 receptor (IL-36R) to treat auto-inflammatory diseases.
Prazer Therapeutics Inc. has identified mitogen-activated protein kinase 14 (MAPK14) inhibitors reported to be useful for the treatment of inflammatory disorders.
Researchers from Hefei Industrial Pharmaceutical Institute Co. Ltd. presented the discovery and preclinical evaluation of novel multifunctional inhibitors as potential anti-inflammatory and analgesic agents.
Researchers from Wenzhou Medical University and affiliated organizations have reported the discovery and preclinical evaluation of novel anti-inflammatory compounds. Synthesis and optimization of a new series of 1-(4-(benzylsulfonyl)-2-nitrophenyl) derivatives resulted in the identification of compound [I] as the lead candidate.
UCB SA has identified imidazotriazine derivatives acting as IL-17 modulators reported to be useful for the treatment of autoimmune and inflammatory disorders.
Researchers from Meiji Seika Pharma Co. Ltd. and affiliated organizations reported the discovery and preclinical evaluation of a novel PD-1 agonist antibody, HM-266, being developed for the treatment of various inflammatory disorders, including autoimmune diseases.
Reservoir Neuroscience Inc. has disclosed prostaglandin E2 receptor EP2 subtype (PTGER2; EP2) antagonists reported to be useful for the treatment of inflammation.
RSS
